Modifiers of Protein Aggregation-From Nonspecific to Specific Interactions

Protein and Peptide Folding, Misfolding, and Non-Folding

Volumn , Issue , 2012, Pages 441-478

  Levy Sakin, Michal ^a   Scherzer Attali, Roni ^a   Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Nonspecific modifiers; Nonspecific to specific interactions; Protein aggregation modifiers

Indexed keywords

EID: 84878076817     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118183373.ch15     Document Type: Chapter

References (214)

1. Cromwell, M. E., Hilario, E., and Jacobson, F. (2006) Protein aggregation and bioprocessing, A APS J 8, E572-E579.
2. Philo, J. S. and Arakawa, T. (2009) Mechanisms of protein aggregation, Curr Pharm Biotechnol 10, 348-351.
3. Dobson, C. M. (2004) Principles of protein folding, misfolding and aggregation, Semin Cell Dev Biol 15, 3-16.
4. Hamada, H., Arakawa, T., and Shiraki, K. (2009) Effect of additives on protein aggregation, C urr Pharm Biotechnol 10, 400-407.
5. Morello, J. P., Petaja - Repo, U. E., Bichet, D. G., and Bouvier, M. (2000) Pharmacological chaperones: A new twist on receptor folding, Trends Pharmacol Sci 21, 466-469.
6. Lentzen, G. and Schwartz, T. (2006) Extremolytes: Natural compounds from extremophiles for versatile applications, Appl Microbiol Biotechnol 72, 12.
7. Hofmeister, F. (1891) About the science of the effect of salts: The contribution of dissolved components to swelling processes, Arch Exp Pathol Pharmakol 28, 29.
8. Lewith, S. (1887) About the science of the effect of salts: The behaviour of the proteins in the blood serum in the presence of salts, Arch Exp Pathol Pharmakol 24, 16.
9. Hofmeister, F. (1887) About the science of the effect of salts: About regulatrities in the protein precipitating effects of salts and the relation of these effects with the physiological behaviour of salts, Arch Exp Pathol Pharmakol 24, 14.
10. Hofmeister, F. (1888) About the science of the effect of salts: About the water withdrawing effect of the salts, Arch Exp Pathol Pharmakol 25, 30.
11. Limbeck, R. V. (1888) About the science of the effect of salts: About the diuretic effect of salts, Arch Exp Pathol Pharmakol 25, 18.
12. Hofmeister, F. (1890) About the science of the effect of salts: Investigations about the swelling process, Arch Exp Pathol Pharmakol 27, 18.
13. Münzer, E. (1898) About the science of the effect of salts: The general effect of salts, Arch Exp Pathol Pharmakol 41, 23.
14. Kunz, W. and Ninham, B. W. (2004) ' Zur Lehre von der Wirkung der Salze ' (about the science of the effect of salts): Franz Hofmeister ' s historical papers, Curr Opin Colloid Interface Sci 9, 19.
15. Collins, K. D. (2006) Ion hydration: Implications for cellular function, polyelectrolytes, and protein crystallization, Biophys Chem 119, 271-281.
16. Zhang, Y. and Cremer, P. S. (2010) Chemistry of Hofmeister anions and osmolytes, Annu Rev Phys Chem 61, 63-83.
17. Zhang, Y. and Cremer, P. S. (2006) Interactions between macromolecules and ions: The Hofmeister series, Curr Opin Chem Biol 10, 658-663.
18. Broering, J. M. and Bommarius, A. S. (2005) Evaluation of Hofmeister effects on the kinetic stability of proteins, J Phys Chem B 109, 20612-20619.
19. Chi, E. Y., Krishnan, S., Randolph, T. W., and Carpenter, J. F. (2003) Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, P harm Res 20, 1325-1336.
20. Curtis, R. A., Ulrich, J., Montaser, A., Prausnitz, J. M., and Blanch, H. W. (2002) Protein - protein interactions in concentrated electrolyte solutions, Biotechnol Bioeng 79, 367-380.
21. Arakawa, T. and Timasheff, S. N. (1984) Mechanism of protein salting in and salting out by divalent cation salts: Balance between hydration and salt binding, Biochemistry 23, 5912-5923.
22. Yeh, V., Broering, J. M., Romanyuk, A., Chen, B., Chernoff, Y. O., and Bommarius, A. S. (2010) The Hofmeister effect on amyloid formation using yeast prion protein, Protein Sci 19, 47-56.
23. Sikkink, L. A. and Ramirez - Alvarado, M. (2008) Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain, Biophys Chem 135, 25-31.
24. Klement, K., Wieligmann, K., Meinhardt, J., Hortschansky, P., Richter, W., and Fandrich, M. (2007) Effect of different salt ions on the propensity of aggregation and on the structure of Alzheimer ' s abeta(1 - 40) amyloid fibrils, J Mol Biol 373, 1321-1333.
25. Jain, S. and Udgaonkar, J. B. (2010) Salt - induced modulation of the pathway of amyloid fibril formation by the mouse prion protein, Biochemistry 49, 7615-7624.
26. Summers, C. A. and Flowers, R. A. (2000) Protein renaturation by the liquid organic salt ethylammonium nitrate, Protein Sci 9, 2001-2008.
27. Lange, C., Patil, G., and Rudolph, R. (2005) Ionic liquids as refolding additives: N' -alkyl and N' - (omega - hydroxyalkyl) N - methylimidazolium chlorides, Protein Sci 14, 2693-2701.
28. Fujita, K., MacFarlane, D. R., and Forsyth, M. (2005) Protein solubilising and stabilising ionic liquids, Chem Commun (Camb) Issue 38, 4804-4806.
29. Fujita, K., Forsyth, M., MacFarlane, D. R., Reid, R. W., and Elliott, G. D. (2006) Unexpected improvement in stability and utility of cytochrome c by solution in biocompatible ionic liquids, Biotechnol Bioeng 94, 1209-1213.
30. Buchfink, R., Tischer, A., Patil, G., Rudolph, R., and Lange, C. (2010) Ionic liquids as refolding additives: Variation of the anion, J Biotechnol 150, 64-72.
31. Holthauzen, L. M. and Bolen, D. W. (2007) Mixed osmolytes: The degree to which one osmolyte affects the protein stabilizing ability of another, Protein Sci 16, 293-298.
32. Roberts, M. F. (2005) Organic compatible solutes of halotolerant and halophilic microorganisms, Saline Systems 1, 5.
33. Harries, D. and Rosgen, J. (2008) A practical guide on how osmolytes modulate macromolecular properties, Methods Cell Biol 84, 679-735.
34. Yancey, P. H. (2005) Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses, J Exp Biol 208, 2819-2830.
35. Yancey, P. H., Blake, W. R., and Conley, J. (2002) Unusual organic osmolytes in deep -sea animals: Adaptations to hydrostatic pressure and other perturbants, Comp Biochem Physiol A Mol Integr Physiol 133, 667-676.
36. Yancey, P. H. (2004) Compatible and counteracting solutes: Protecting cells from the Dead Sea to the deep sea, Sci Prog 87, 1-24.
37. Brown, A. D. and Simpson, J. R. (1972) Water relations of sugar - tolerant yeasts: The role of intracellular polyols, J Gen Microbiol 72, 589-591.
38. Gerlsma, S. Y. and Stuur, E. R. (1972) The effect of polyhydric and monohydric alcohols on the heat - induced reversible denaturation of lysozyme and ribonuclease, Int J Pept Protein Res 4, 377-383.
39. Yancey, P. H. and Burg, M. B. (1990) Counteracting effects of urea and betaine in mammalian cells in culture, Am J Physiol 258, R198-R204.
40. Yancey, P. H., Clark, M. E., Hand, S. C., Bowlus, R. D., and Somero, G. N. (1982) Living with water stress: Evolution of osmolyte systems, Science 217, 1214-1222.
41. Yancey, P. H., Fyfe - Johnson, A. L., Kelly, R. H., Walker, V. P., and Aunon, M. T. (2001) Trimethylamine oxide counteracts effects of hydrostatic pressure on proteins of deep -sea teleosts, J Exp Zool 289, 172-176.
42. Yancey, P. H., Heppenstall, M., Ly, S., Andrell, R. M., Gates, R. D., Carter, V. L., and Hagedorn, M. (2010) Betaines and dimethylsulfoniopropionate as major osmolytes in cnidaria with endosymbiotic dinoflagellates, Physiol Biochem Zool 83, 167-173.
43. Yancey, P. H., Rhea, M. D., Kemp, K. M., and Bailey, D. M. (2004) Trimethylamine oxide, betaine and other osmolytes in deep - sea animals: Depth trends and effects on enzymes under hydrostatic pressure, Cell Mol Biol (Noisy - le - grand) 50, 371-376.
44. Bennion, B. J. and Daggett, V. (2004) Counteraction of urea - induced protein denaturation by trimethylamine N - oxide: A chemical chaperone at atomic resolution, Proc Natl Acad Sci U S A 101, 6433-6438.
45. Lin, T. Y. and Timasheff, S. N. (1994) Why do some organisms use a urea - methylamine mixture as osmolyte? Thermodynamic compensation of urea and trimethylamine N - oxide interactions with protein, Biochemistry 33, 12695-12701.
46. Perlmutter, D. H. (2002) Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking, Pediatr Res 52, 832-836.
47. Tatzelt, J., Prusiner, S. B., and Welch, W. J. (1996) Chemical chaperones interfere with the formation of scrapie prion protein, EMBO J 15, 6363-6373.
48. Welch, W. J. and Brown, C. R. (1996) Influence of molecular and chemical chaperones on protein folding, Cell Stress Chaperones 1, 109-115.
49. Gekko, K. and Timasheff, S. N. (1981) Mechanism of protein stabilization by glycerol: Preferential hydration in glycerol - water mixtures, Biochemistry 20, 4667-4676.
50. Gekko, K. and Timasheff, S. N. (1981) Thermodynamic and kinetic examination of protein stabilization by glycerol, Biochemistry 20, 4677-4686.
51. Baldwin, R. L. (1996) How Hofmeister ion interactions affect protein stability, Biophys J 71, 2056-2063.
52. Hummer, G., Garde, S., Garcia, A. E., Paulaitis, M. E., and Pratt, L. R. (1998) The pressure dependence of hydrophobic interactions is consistent with the observed pressure denaturation of proteins, Proc Natl Acad Sci U S A 95, 1552-1555.
53. Gur, E., Biran, D., Gazit, E., and Ron, E. Z. (2002) In vivo aggregation of a single enzyme limits growth of Escherichia coli at elevated temperatures, Mol Microbiol 46, 1391-1397.
54. Feng, S. and Yan, Y. B. (2008) Effects of glycerol on the compaction and stability of the wild type and mutated rabbit muscle creatine kinase, Proteins 71, 844-854.
55. Barreca, D., Lagana, G., Ficarra, S., Tellone, E., Leuzzi, U., Magazu, S., Galtieri, A., and Bellocco, E. (2010) Anti - aggregation properties of trehalose on heat - induced secondary structure and conformation changes of bovine serum albumin, Biophys Chem 147, 146-152.
56. Ignatova, Z. and Gierasch, L. M. (2006) Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant, Proc Natl Acad Sci U S A 103, 13357-13361.
57. Nayak, A., Lee, C. C., McRae, G. J., and Belfort, G. (2009) Osmolyte controlled fibrillation kinetics of insulin: New insight into fibrillation using the preferential exclusion principle, B iotechnol Prog 25, 1508-1514.
58. Fung, J., Darabie, A. A., and McLaurin, J. (2005) Contribution of simple saccharides to the stabilization of amyloid structure, Biochem Biophys Res Commun 328, 1067-1072.
59. Kim, Y. S., Cape, S. P., Chi, E., Raffen, R., Wilkins - Stevens, P., Stevens, F. J., Manning, M. C., Randolph, T. W., Solomon, A., and Carpenter, J. F. (2001) Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains, J Biol Chem 276, 1626-1633.
60. De Young, L. R., Dill, K. A., and Fink, A. L. (1993) Aggregation and denaturation of apomyoglobin in aqueous urea solutions, Biochemistry 32, 3877-3886.
61. Tsumoto, K., Ejima, D., Kumagai, I., and Arakawa, T. (2003) Practical considerations in refolding proteins from inclusion bodies, Protein Expr Purif 28, 1-8.
62. Dunbar, J., Yennawar, H. P., Banerjee, S., Luo, J., and Farber, G. K. (1997) The effect of denaturants on protein structure, Protein Sci 6, 1727-1733.
63. O ' Brien, E. P., Dima, R. I., Brooks, B., and Thirumalai, D. (2007) Interactions between hydrophobic and ionic solutes in aqueous guanidinium chloride and urea solutions: Lessons for protein denaturation mechanism, J Am Chem Soc 129, 7346-7353.
64. Lim, W. K., Rosgen, J., and Englander, S. W. (2009) Urea, but not guanidinium, destabilizes proteins by forming hydrogen bonds to the peptide group, Proc Natl Acad Sci U S A 106, 2595-2600.
65. Kendrick, B. S., Cleland, J. L., Lam, X., Nguyen, T., Randolph, T. W., Manning, M. C., and Carpenter, J. F. (1998) Aggregation of recombinant human interferon gamma: Kinetics and structural transitions, J Pharm Sci 87, 1069-1076.
66. Kim, J. R., Muresan, A., Lee, K. Y., and Murphy, R. M. (2004) Urea modulation of beta - amyloid fibril growth: Experimental studies and kinetic models, Protein Sci 13, 2888-2898.
67. Wang, X. Y., Meng, F. G., and Zhou, H. M. (2003) Inactivation and conformational changes of creatine kinase at low concentrations of hexafluoroisopropanol solutions, Biochem Cell Biol 81, 327-333.
68. Yang, H. P. and Zhou, H. M. (1997) Conformational changes of creatine kinase in trifluoroethanol solutions, Biochem Mol Biol Int 43, 1297-1304.
69. Bohidar, H. B. and Mohanty, B. (2004) Anomalous self - assembly of gelatin in ethanol -water marginal solvent, Phys Rev E 69, 021902 - 1-021902 - 9.
70. Roccatano, D., Colombo, G., Fioroni, M., and Mark, A. E. (2002) Mechanism by which 2,2,2 - trifluoroethanol/water mixtures stabilize secondary - structure formation in peptides: A molecular dynamics study, Proc Natl Acad Sci U S A 99, 12179-12184.
71. Sen, P., Ahmad, B., Rabbani, G., and Khan, R. H. (2010) 2,2,2 - Trifluroethanol induces simultaneous increase in alpha - helicity and aggregation in alkaline unfolded state of bovine serum albumin, Int J Biol Macromol 46, 250-254.
72. Sabate, R. and Estelrich, J. (2003) Disaggregating effects of ethanol at low concentration on beta - poly - L - lysines, I nt J Biol Macromol 32, 10-16.
73. Cao, A., Hu, D., and Lai, L. (2004) Formation of amyloid fibrils from fully reduced hen egg white lysozyme, Protein Sci 13, 319-324.
74. Dzwolak, W., Grudzielanek, S., Smirnovas, V., Ravindra, R., Nicolini, C., Jansen, R., Loksztejn, A., Porowski, S., and Winter, R. (2005) Ethanol - perturbed amyloidogenic self - assembly of insulin: Looking for origins of amyloid strains, Biochemistry 44, 8948-8958.
75. Grudzielanek, S., Velkova, A., Shukla, A., Smirnovas, V., Tatarek - Nossol, M., Rehage, H., Kapurniotu, A., and Winter, R. (2007) Cytotoxicity of insulin within its self -assembly and amyloidogenic pathways, J Mol Biol 370, 372-384.
76. Shen, C. L. and Murphy, R. M. (1995) Solvent effects on self - assembly of beta - amyloid peptide, B iophys J 69, 640-651.
77. Hirota - Nakaoka, N., Hasegawa, K., Naiki, H., and Goto, Y. (2003) Dissolution of beta2 -microglobulin amyloid fibrils by dimethylsulfoxide, J Biochem 134, 159-164.
78. Sonesson, A. W., Blom, H., Hassler, K., Elofsson, U. M., Callisen, T. H., Widengren, J., and Brismar, H. (2008) Protein - surfactant interactions at hydrophobic interfaces studied with total internal reflection fluorescence correlation spectroscopy (TIR - FCS), J Colloid Interface Sci 317, 449-457.
79. Chou, D. K., Krishnamurthy, R., Randolph, T. W., Carpenter, J. F., and Manning, M. C. (2005) Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation, J Pharm Sci 94, 1368-1381.
80. Randolph, T. W. and Jones, L. S. (2002) Surfactant - protein interactions, Pharm Biotechnol 13, 159-175.
81. Giehm, L., Oliveira, C. L., Christiansen, G., Pedersen, J. S., and Otzen, D. E. (2010) SDS - induced fibrillation of alpha - synuclein: An alternative fibrillation pathway, J Mol Biol 401, 115-133.
82. Hung, Y. T., Lin, M. S., Chen, W. Y., and Wang, S. S. (2010) Investigating the effects of sodium dodecyl sulfate on the aggregative behavior of hen egg - white lysozyme at acidic pH, Colloids Surf B Biointerfaces 81, 141-151.
83. Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., Barlow, E., Ebert, U., and Hillen, H. (2005) Globular amyloid beta - peptide oligomer - A homogenous and stable neuropathological protein in Alzheimer ' s disease, J Neurochem 95, 834-847.
84. Cao, M., Han, Y., Wang, J., and Wang, Y. (2007) Modulation of fibrillogenesis of amyloid beta(1 - 40) peptide with cationic gemini surfactant, J Phys Chem B 111, 13436-13443.
85. Wang, S. S., Liu, K. N., and Han, T. C. (2010) Amyloid fibrillation and cytotoxicity of insulin are inhibited by the amphiphilic surfactants, Biochim Biophys Acta 1802, 519-530.
86. Samiotakis, A., Wittung - Stafshede, P., and Cheung, M. S. (2009) Folding, stability and shape of proteins in crowded environments: Experimental and computational approaches, I nt J Mol Sci 10, 572-588.
87. Minton, A. P. (2001) The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media, J Biol Chem 276, 10577-10580.
88. Ellis, R. J. (2001) Macromolecular crowding: Obvious but underappreciated, Trends Biochem Sci 26, 597-604.
89. Kinjo, A. R. and Takada, S. (2002) Effects of macromolecular crowding on protein folding and aggregation studied by density functional theory: Dynamics, Phys Rev E Stat Nonlin Soft Matter Phys 66, 051902.
90. van den Berg, B., Ellis, R. J., and Dobson, C. M. (1999) Effects of macromolecular crowding on protein folding and aggregation, EMBO J 18, 6927-6933.
91. van den Berg, B., Wain, R., Dobson, C. M., and Ellis, R. J. (2000) Macromolecular crowding perturbs protein refolding kinetics: Implications for folding inside the cell, EMBO J 19, 3870-3875.
92. Shtilerman, M. D., Ding, T. T., and Lansbury, P. T., Jr. (2002) Molecular crowding accelerates fibrillization of alpha - synuclein: Could an increase in the cytoplasmic protein concentration induce Parkinson ' s disease? Biochemistry 41, 3855-3860.
93. Hatters, D. M., Minton, A. P., and Howlett, G. J. (2002) Macromolecular crowding accelerates amyloid formation by human apolipoprotein C - II, J Biol Chem 277, 7824-7830.
94. Zhou, Z., Fan, J. B., Zhu, H. L., Shewmaker, F., Yan, X., Chen, X., Chen, J., Xiao, G. F., Guo, L., and Liang, Y. (2009) Crowded cell - like environment accelerates the nucleation step of amyloidogenic protein misfolding, J Biol Chem 284, 30148-30158.
95. Zhou, B. R., Zhou, Z., Hu, Q. L., Chen, J., and Liang, Y. (2008) Mixed macromolecular crowding inhibits amyloid formation of hen egg white lysozyme, Biochim Biophys Acta 1784, 472-480.
96. Zhao, J. H., Liu, H. L., Lin, H. Y., Huang, C. H., Fang, H. W., Chen, S. S., Ho, Y., Tsai, W. B., and Chen, W. Y. (2007) Chemical chaperone and inhibitor discovery: Potential treatments for protein conformational diseases, Perspect Med Chem 1, 39-48.
97. Virchow, R. (1853) Über eine im gehirn und rückenmark des menschen aufgefundene substanz mit der chemischen reaktion der cellulose, Virchows Arch 6, 135-138.
98. Aguzzi, A. and O ' Conno, T. (2010) Protein aggregation diseases: Pathogenicity and therapeutic perspectives, Nat Rev 9, 237-248.
99. Amijee, H., Madine, J., Middletona, D. A., and Doig, A. J. (2009) Inhibitors of protein aggregation and toxicity, Biochem Soc Trans 37, 692-696.
100. Wyatt, A. R., Yerbury, J. J., Poon, S., and Wilson, M. R. (2009) Therapeutic targets in extracellular protein deposition diseases, Curr Med Chem 16, 2855-2866.
101. Smith, H. J., Simons, C., and Sewell, R. D. E. (2008) Protein misfolding in neurodegenerative diseases: Mechanisms and therapeutic strategies, illustrated ed. CRC Press, Boca Raton, FL.
102. Lorenzo, A. and Yankner, B. A. (1994) Beta - amyloid neurotoxicity requires fibril formation and is inhibited by Congo red, Proc Natl Acad Sci U S A 91, 12243-12247.
103. Lee, V. M. (2002) Amyloid binding ligands as Alzheimer ' s disease therapies, Neurobiol Aging 23, 1039-1042.
104. Poli, G., Ponti, W., Carcassola, G., Ceciliani, F., Colombo, L., Dall ' Ara, P., Gervasoni, M., Giannino, M. L., Martino, P. A., Pollera, C., Villa, S., and Salmona, M. (2003) In vitro evaluation of the anti - prionic activity of newly synthesized Congo red derivatives, Arzneimittelforschung 53, 875-888.
105. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism, C hem Biol Drug Des 67, 27-37.
106. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the α - synuclein protofibril by a dopamine - α - synuclein adduct, Science 294, 1346-1349.
107. Spillantini, M. G., Schmidt, M. L., Lee, V. M. Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α - Synuclein in Lewy bodies, Nature 388, 839-840.
108. Levy, M., Porat, Y., Bacharach, E., Shalev, D. E., and Gazit, E. (2008) Phenolsulfonphthalein, but not phenolphthalein, inhibits amyloid fibril formation: Implications for the modulation of amyloid self - assembly, Biochemistry 47, 5896-5904.
109. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., and Wanker, E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off - pathway oligomers, Nat Struct Mol Biol 15, 558-566.
110. Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T., and Betsholtz, C. (1990) Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation, Proc Natl Acad Sci U S A 87, 5036-5040.
111. Szegedi, V., Juhasz, G., Rozsa, E., Juhasz - Vedres, G., Datki, Z., Fulop, L., Bozso, Z., Lakatos, A., Laczko, I., Farkas, T., Kis, Z., Toth, G., Soos, K., Zarandi, M., Budai, D., Toldi, J., and Penke, B. (2006) Endomorphin - 2, an endogenous tetrapeptide, protects against Abeta1 - 42 in vitro and in vivo, FASEB J 20, 1191-1193.
112. Frew, T., Powis, G., Berggren, M., Gallegos, A., Abraham, R. T., Ashendel, C. L., Zalkow, L. H., Hudson, C., Gruszecka - Kowalik, E., and Burgess, E. M. (1995) Novel quinone antiproliferative inhibitors of phosphatidylinositol - 3 - kinase, A nticancer Drug Des 10, 347-359.
113. Gulielmo, B. J. and MacDougall, C. (2004) Pharmacokinetics of valaciclovir, J Antimicrob Chemother 6, 899-901.
114. Ono, K., Hasegawa, K., Naiki, H., and Yamada, M. (2005) Preformed β - amyloid fibrils are destabilized by coenzyme Q10 in vitro, Biochem Biophys Res Commun 330, 111-116.
115. Tomiyama, T., Kaneko, H., Kataoka, K., Asano, S., and Endo, N. (1997) Rifampicin inhibits the toxicity of pre - aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid - cell interaction, Biochem J 322, 859-865.
116. Lieu, V. H., Wu, J. W., Wang, S. S., and Wu, C. H. (2007) Inhibition of amyloid fibrillization of hen egg - white lysozymes by rifampicin and p - benzoquinone, Biotechnol Prog 23, 698-706.
117. Bolognesi, M. L., Banzi, R., Bartolini, M., Cavalli, A., Tarozzi, A., Andrisano, V., Minarini, A., Rosini, M., Tumiatti, V., Bergamini, C., Fato, R., Lenaz, G., Hrelia, P., Cattaneo, A., Recanatini, M., and Melchiorre, C. (2007) Novel class of quinone - bearing polyamines as multi - target - directed ligands to combat Alzheimer ' s disease, J Med Chem 50, 4882-4897.
118. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer ' s paired helical filaments in vitro and in cells, J Biol Chem 280, 3628-3635.
119. Convertino, M., Pellarin, R., Catto, M., Carotti, A., and Caflisch, A. (2009) 9,10 - Anthraquinone hinders β - aggregation: How does a small molecule interfere with Aβ - peptide amyloid fibrillation? Prot Sci 18, 792-800.
120. Necula, M., Kayed, R., Milton, S., and Glabe, C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization Pathways are independent and distinct, J Biol Chem 282, 10311-10324.
121. Scherzer - Attali, R., Pellarin, R., Convertino, M., Frydman - Marom, A., Egoz - Matia, N., Peled, S., Levy - Sakin, M., Shalev, D. E., Caflisch, A., Gazit, E., and Segal, D. (2010) Complete phenotypic recovery of an Alzheimer ' s disease model by a quinone - tryptophan hybrid aggregation inhibitor, PLoS ONE 5, e11101.
122. de Sáalves, F. R., Barreiro, E. J., and Fraga, C. A. (2009) From nature to drug discovery: The indole scaffold as a "privileged structure," Mini Rev Med Chem 7, 782-793.
123. Cohen, T., Frydman - Marom, A., Rechter, M., and Gazit, E. (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives, Biochemistry 45, 4727-4735.
124. Latawiec, D., Herrera, F., Bek, A., Losasso, V., Candotti, M., Benetti, F., Carlino, E., Kranjc, A., Lazzarino, M., Gustincich, S., Carloni, P., and Legname, G. (2010) Modulation of alpha - synuclein aggregation by dopamine analogs, PLoS ONE 5, e9234.
125. Jensen, P. H., Sorensen, E. S., Petersen, T. E., Gliemann, J., and Rasmussen, L. K. (1995) Residues in the synuclein consensus motif of the alpha - synuclein fragment, NAC, participate in transglutaminase - catalysed cross - linking to Alzheimer - disease amyloid beta A4 peptide, Biochem J 310, (Pt 1), 91-94.
126. Windisch, M., Hutter - Paier, B., Schreiner, E., and Wronski, R. (2004) Beta - Synuclein -derived peptides with neuroprotective activity: An alternative treatment of neurodegenerative disorders? J Mol Neurosci 24, 155-165.
127. Sunde, M. and Blake, C. C. F. (1997) The structure of amyloid fibrils by electron microscopy and X - ray diffraction, Adv Protein Chem 50, 123-159.
128. Rochet, J. C. and Lansbury, P. T. (2000) Amyloid fibrillogenesis: Themes and variations, Curr Opin Struct Biol 10, 60-68.
129. Stefani, M. and Dobson, C. M. (2003) Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution, J Mol Med 81, 678-699.
130. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases, Nat Rev Neurosci 4, 49-60.
131. Gazit, E. (2002) A possible role for p - stacking in self - assembly of amyloid fibrils, FASEB J 16, 77-83.
132. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castaño, E. M., and Frangione, B. (1998) Beta - sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer ' s therapy, Nat Med 4, 822-826.
133. Findeis, M. A., Musso, G. M., Arico - Muendel, C. C., Benjamin, H. W., Hundal, A. M., Lee, J. J., Chin, J., Kelley, M., Wakefield, J., Hayward, N. J., and Molineaux, S. M. (1999) Modified - peptide inhibitors of amyloid - beta - peptide polymerization, Biochemistry 38, 6791-6800.
134. Kapurniotu, A., Schmauder, A., and Tenidis, K. (2002) Structure - based design and study of non - amyloidogenic, double N - methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity, J Mol Biol 315, 339-350.
135. Gilead, S. and Gazit, E. (2004) Inhibition of amyloid fibril formation by peptide analogues modified with α - aminoisobutyric acid, Angew Chem Int Ed Engl 43, 4041-4044.
136. Frydman - Marom, A., Rechter, M., Shefler, I., Bram, Y., Shalev, D. E., and Gazit, E. (2009) Cognitive - performance recovery of Alzheimer ' s disease model mice by modulation of early soluble amyloidal assemblies, Angew Chem Int Ed Engl 48, 1981-1986.
137. Kaufman, R. J. (1999) Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls, Genes Dev 13, 1211-1233.
138. Cohen, F. E. and Kelly, J. W. (2003) Therapeutic approaches to protein misfolding diseases, Nature 426, 905-909.
139. Kopito, R. R. (1999) Biosynthesis and degradation of CFTR, Physiol Rev 79, S167-S173.
140. Kerem, B. S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., and Tsui, L. C. (1989) Identification of the cystic fibrosis gene: Genetic analysis, Science 245, 1073-1080.
141. Amaral, M. D. (2006) Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease, J Inherit Metab Dis 29, 477-487.
142. Robert, J., Auzan, C., Ventura, M. A., and Clauser, E. (2005) Mechanisms of cell -surface rerouting of an endoplasmic reticulum - retained mutant of the vasopressin V1b/ V3 receptor by a pharmacological chaperone, J Biol Chem 280, 42198-42206.
143. Ulloa - Aguirre, A., Janovick, J. A., Brothers, S. P., and Conn, P. M. (2004) Pharmacologic rescue of conformationally - defective proteins: Implications for the treatment of human disease, T raffic 5, 821-837.
144. Gong, Q., Jones, M. A., and Zhou, Z. (2006) Mechanisms of pharmacological rescue of trafficking - defective hERG mutant channels in human long QT syndrome, J Biol Chem 281, 4069-4074.
145. Powell, K. and Zeitlin, P. L. (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting, Adv Drug Deliv Rev 54, 1395-1408.
146. Egan, M. E., Glockner - Pagel, J., Ambrose, C., Cahill, P. A., Pappoe, L., Balamuth, N., Cho, E., Canny, S., Wagner, C. A., Geibel, J., and Caplan, M. J. (2002) Calcium - pump inhibitors induce functional surface expression of Delta F508 - CFTR protein in cystic fibrosis epithelial cells, Nat Med 8, 485-492.
147. Norez, C., Heda, G. D., Jensen, T., Kogan, I., Hughes, L. K., Auzanneau, C., Derand, R., Bulteaux - Pignoux, L., Li, C., Ramjeesingh, M., Sheppard, D. N., Bear, C. E., Riordan, J. R., and Becq, F. (2004) Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods, J Cyst Fibros 3, Suppl 2, 119-121.
148. Norez, C., Antigny, F., Becq, F., and Vandebrouck, C. (2006) Maintaining low Ca2 + level in the endoplasmic reticulum restores abnormal endogenous F508del - CFTR trafficking in airway epithelial cells, Traffic 7, 562-573.
149. Wang, Y., Bartlett, M. C., Loo, T. W., and Clarke, D. M. (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones, Mol Pharmacol 70, 297-302.
150. Norez, C., Noel, S., Wilke, M., Bijvelds, M., Jorna, H., Melin, P., DeJonge, H., and Becq, F. (2006) Rescue of functional delF508 - CFTR channels in cystic fibrosis epithelial cells by the alpha - glucosidase inhibitor miglustat, FEBS Lett 580, 2081-2086.
151. Becq, F., Mettey, Y., Gray, M. A., Galietta, L. J., Dormer, R. L., Merten, M., Metaye, T., Chappe, V., Marvingt - Mounir, C., Zegarra - Moran, O., Tarran, R., Bulteau, L., Dérand, R., Pereira, M. M., McPherson, M. A., Rogier, C., Joffre, M., Argent, B. E., Sarrouilhe, D., Kammouni, W., Figarella, C., Verrier, B., Gola, M., and Vierfond, J. M. (1999) Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel, J Biol Chem 274, 27415-27425.
152. Dormer, R. L., Derand, R., McNeilly, C. M., Mettey, Y., Bulteau - Pignoux, L., Metaye, T., Vierfond, J. M., Gray, M. A., Galietta, L. J. V., Morris, M. R., Pereira, M. M., Doull, I. J., Becq, F., and McPherson, M. A. (2001) Correction of delF508 - CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells, J Cell Sci 114, 4073-4081.
153. Marivingt - Mounir, C., Norez, C., Derand, R., Bulteau - Pignoux, L., Nguyen - Huy, D., Viossat, B., Morgant, G., Becq, F., Vierfond, J. M., and Mettey, Y. (2004) Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild - type and mutant cystic fibrosis transmembrane conductance regulator channels, J Med Chem 47, 962-972.
154. Melin, P., Thoreau, V., Norez, C., Bilan, F., Kitzis, A., and Becq, F. (2004) The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein, Biochem Pharmacol 67, 2187-2196.
155. Dormer, R. L., McNeilly, C. M., Morris, M. R., Pereira, M. M., Doull, I. J., Becq, F., Mettey, Y., Vierfond, J. M., and McPherson, M. A. (2001) Localisation of wild - type and DeltaF508 - CFTR in nasal epithelial cells, Pflugers Arch 443, S117-S120.
156. Stratford, F. L., Pereira, M. M., Becq, F., McPherson, M. A., and Dormer, R. L. (2003) Benzo - (c)quinolizinium drugs inhibit degradation of Delta F508 - CFTR cytoplasmic domain, B iochem Biophys Res Commun 3 00, 524-530.
157. Nowak, R. J., Cuny, G. D., Choi, S., Lansbury, P. T., and Ray, S. S. (2010) Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase - 1 linked to familial amyotrophic lateral sclerosis using computational methods, J Med Chem 53, 2709-2718.
158. Brady, R. O. (1997) Gaucher ' s disease: Past, present and future, Baillieres Clin Haematol 10, 621-634.
159. Sawkar, A. R., Cheng, W. C., Beutler, E., Wong, C. H., Balch, W. E., and Kelly, J. W. (2002) Chemical chaperones increase the cellular activity of N370S beta - glucosidase: A therapeutic strategy for Gaucher disease, Proc Natl Acad Sci U S A 99, 15428-15433.
160. Sawkar, A. R., D ' Haeze, W., and Kelly, J. W. (2006) Therapeutic strategies to ameliorate lysosomal storage disorders; a focus on Gaucher disease, Cell Mol Life Sci 63, 1179-1192.
161. Fan, J. - Q. (2003) A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity, Trends Pharmacol Sci 24, 355-360.
162. Butters, T. D. (2007) Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders, Expert Opin Pharmacother 8, 427-435.
163. Grabowski, G. A. (2008) Treatment perspectives for the lysosomal storage diseases, Expert Opin Emerg Drugs 13, 197-211.
164. Di{dotless}′az, L., Bujons, J., Casas, J., Llebaria, A., and Delgado, A. (2010) Click chemistry approach to new N - substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease, J Med Chem 53, 5248-5255.
165. Zatta, P., Lucchini, R., Van Rensburg, S. J., and Taylor, A. (2003) The role of metals in neurodegenerative processes: Aluminum, manganese and zinc, Brain Res Bull 62, 15-28.
166. Zatta, P. (2003) Metal ions and neurodegenerative disorders, World Scientific, Singapore and London.
167. Liu, G., Huang, W., Moir, R., Vanderburg, C. R., Lai, B., Peng, Z., Tanzi, R. E., Rogers, J. T., and Huang, X. (2006) Metal exposure and Alzheimer ' s pathogenesis, J Struct Biol 155, 45-51.
168. Morgan, D. M., Dong, J., Jacob, J., Lu, K., Apkarian, R. P., Thiyagarajan, P., and Lynn, D. G. (2002) Metal switch for amyloid formation: Insight into the structure of the nucleus, J Am Chem Soc 124, 12644-12645.
169. Bush, A. I. (2003) The metallobiology of Alzheimer ' s disease, Trends Neurosci 26, 207-214.
170. House, E., Collingwod, J., Khan, A., Korchazkina, O., Berthon, G., and Exley, C. (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer ' s disease, J Alzheimer Dis 6, 291-301.
171. Ricchelli, F., Drago, D., Filippi, B., Tognon, G., and Zatta, P. (2005) Aluminum triggered structural modifications and aggregation of betaamyloids, Cell Mol Life Sci 62, 1724-1733.
172. Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R., and Li, Q. X. (2005) Metals and amyloid - β in Alzheimer ' s disease, Int J Exp Pathol 86, 147-159.
173. Yoshiike, Y., Tanemura, K., Murayama, O., Akagi, T., Murayama, M., Sato, S., Sun, X., Tanaka, N., and Takashima, A. (2001) New insights on how metals disrupt amyloid beta - aggregation and their effects on amyloid - beta cytotoxicity, J Biol Chem 276, 32293-32299.
174. Huang, X., Atwood, C. S., Moir, R., Hartshorn, M. A., Tanzi, R. E., and Bush, A. I. (2004) Trace elements contamination initiates the apparent autoaggregation, amyloidosis, and oligomerization of Alzheimer ' s Abeta peptides, J Biol Inorg Chem 9, 954-960.
175. Mantyh, P. W., Ghilardi, J. R., Rogers, S., DeMaster, E., Allen, C. J., Stimson, E. R., and Maggio, J. E. (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta - amyloid peptide, J Neurochem 61, 1171-1174.
176. Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., and Bush, A. I. (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis, J Biol Chem 273, 12817-12826.
177. Beauchemin, D. and Kisilevsky, R. (1998) A method based on ICP - MS for the analysis of Alzheimer ' s amyloid plaques, Anal Chem 70, 1026-1029.
178. Drago, D., Bolognin, S., and Zatta, P. (2008) Role of metal ions in the A β oligomerization in Alzheimer ' s disease and in other neurological disorders, Curr Alzheimer Res 5, 500-507.
179. Kawahara, M., Kato, M., and Kuroda, Y. (2001) Effects of aluminium on the neurotoxicity of primary cultured neurons and on the aggregation of beta - amyloid protein, Brain Res Bull 55, 211-217.
180. Kawahara, M. (2005) Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases, J Alzheimer Dis 8, 171-182.
181. Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., and Marsden, C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson ' s disease, J Neurochem 52, 1830-1836.
182. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J Neurochem 52, 515-520.
183. Bisaglia, M., Tessari, I., Mammi, S., and Bubacco, L. (2009) Interaction between α -synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson ' s disease, Neuromol Med 11, 239-251.
184. Paik, S. R., Shin, H. J., Lee, J. H., Chang, C. S., and Kim, J. (1999) Copper(II) - induced self - oligomerization of alpha - synuclein, Biochem J 340, 821-828.
185. Uversky, V. N., Li, J., and Fink, A. L. (2001) Metal - triggered structural transformations, aggregation, and fibrillation of human alpha - synuclein. A possible molecular NK between Parkinson' s disease and heavy metal exposure, J Biol Chem 276, 44284-44296.
186. Binolfi, A., Rasia, R. M., Bertoncini, C. W., Ceolin, M., Zweckstetter, M., Griesinger, C., Jovin, T. M., and Fernández, C. O. (2006) Interaction of alpha - synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement, J Am Chem Soc 128, 9893-9901.
187. Dexter, D. T., Carayon, A., Javoy - Agid, F., Agid, Y., Wells, F. R., Daniel, S. E., Lees, A. J., Jenner, P., and Marsden, C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson ' s disease and other neurodegenerative diseases affecting the basal ganglia, Brain 114, 1953-1975.
188. Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., Karatekin, E., Kleinman, M. H., Turro, N., Hornykiewicz, O., and Zucca, F. A. (2004) The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging, Proc Natl Acad Sci U S A 101, 9843-9848.
189. Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P., and Wolozin, B. (2002) Magnesium inhibits spontaneous and iron - induced aggregation of alpha - synuclein, J Biol Chem 277, 16116-16123.
190. Bharathi, K. S. J. Rao (2007) Thermodynamics imprinting reveals differential binding of metals to alpha - synuclein: Relevance to Parkinson ' s disease, Biochem Biophys Res Commun 359, 115-120.
191. Kostka, M., Hogen, T., Danzer, K. M., Levin, J., Habeck, M., Wirth, A., Wagner, R., Glabe, C. G., Finger, S., Heinzelmann, U., Garidel, P., Duan, W., Ross, C. A., Kretzschmar, H., and Giese, A. (2008) Single particle characterization of iron - induced pore - forming alpha - synuclein oligomers, J Biol Chem 283, 10992-11003.
192. Pall, H. S., Williams, A. C., Blake, D. R., Lunec, J., Gutteridge, J. M., Hall, M., and Taylor, A. (1987) Raised cerebrospinal - fluid copper concentration in Parkinson ' s disease, Lancet 2, 238-241.
193. Rasia, R. M., Bertoncini, C. W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., Griesinger, C., Jovin, T. M., and Fernández, C. O. (2005) Structural characterization of copper(II) binding to alpha - synuclein: Insights into the bioinorganic chemistry of Parkinson' s disease, Proc Natl Acad Sci U S A 102, 4294-4299.
194. Brown, D. R., Qin, K., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., von Bohlen, A., Schulz - Schaeffer, W., Giese, A., Westaway, D., and Kretzschmar, H. (1997) The cellular prion protein binds copper in vivo, Nature 390, 684-687.
195. Sung, Y. H., Rospigliosi, C., and Eliezer, D. (2006) NMR mapping of copper binding sites in alpha - synuclein, Biochim Biophys Acta 1764, 5-12.
196. Binolfi, A., Lamberto, G. R., Duran, R., Quintanar, L., Bertoncini, C. W., Souza, J. M., Cerveñansky, C., Zweckstetter, M., Griesinger, C., and Fernández, C. O. (2008) Site - specific interactions of Cu(II) with alpha and beta - synuclein: Bridging the molecular gap between metal binding and aggregation, J Am Chem Soc 130, 11801-11812.
197. Ricchelli, F., Buggio, R., Drago, D., Forloni, G., Negro, A., Tognon, G., and Zatta, P. (2006) Aggregation/fibrillogenesis of recombinant human prion protein and Gestmann -Straussler - Scheinker disease peptides in the presence of metal ions, Biochemistry 45, 6724-6732.
198. Mihaela, N., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., and Glabe, C. G. (2007) Methylene blue inhibits amyloid A β oligomerization by promoting fibrillization, B iochemistry 46, 8850-8860.
199. Qi, W., Zhang, A., Good, T. A., and Fernandez, E. J. (2009) Two disaccharides and trimethylamine N - oxide affect Abeta aggregation differently, but all attenuate oligomer -induced membrane permeability, Biochemistry 48, 8908-8919.
200. Liu, R., Barkhordarian, H., Emadi, S., Park, C. B., and Sierks, M. R. (2005) Trehalose differentially inhibits aggregation and neurotoxicity of beta - amyloid 40 and 42, Neurobiol Dis 20, 74-81.
201. Ueda, T., Nagata, M., Monji, A., Yoshida, I., Tashiro, N., and Imoto, T. (2002) Effect of sucrose on formation of the beta - amyloid fibrils and D - aspartic acids in Abeta 1-42, Biol Pharm Bull 25, 375-378.
202. Ryu, J., Kanapathipillai, M., Lentzen, G., and Park, C. B. (2008) Inhibition of beta -amyloid peptide aggregation and neurotoxicity by alpha - d - mannosylglycerate, a natural extremolyte, P eptides 29, 578-584.
203. Kanapathipillai, M., Lentzen, G., Sierks, M., and Park, C. B. (2005) Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer ' s beta - amyloid, FEBS Lett 579, 4775-4780.
204. Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V. N., and Fink, A. L. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism, Biochemistry 40, 6036-6046.
205. Arora, A., Ha, C., and Park, C. B. (2004) Inhibition of insulin amyloid formation by small stress molecules, FEBS Lett 564, 121-125.
206. Vilasi, S., Iannuzzi, C., Portaccio, M., Irace, G., and Sirangelo, I. (2008) Effect of trehalose on W7FW14F apomyoglobin and insulin fibrillization: New insight into inhibition activity, Biochemistry 47, 1789-1796.
207. Bomhoff, G., Sloan, K., McLain, C., Gogol, E. P., and Fisher, M. T. (2006) The effects of the flavonoid baicalein and osmolytes on the Mg2 + accelerated aggregation/ fibrillation of carboxymethylated bovine 1SS - alpha - lactalbumin, Arch Biochem Biophys 453, 75-86.
208. Hegde, M. L. and Rao, K. S. (2007) DNA induces folding in alpha - synuclein: Understanding the mechanism using chaperone property of osmolytes, Arch Biochem Biophys 464, 57-69.
209. Uversky, V. N., Li, J., and Fink, A. L. (2001) Trimethylamine - N - oxide - induced folding of alpha - synuclein, F EBS Lett 509, 31-35.
210. Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N. R., Doi, H., Kurosawa, M., Nekooki, M., and Nukina, N. (2004) Trehalose alleviates polyglutamine - mediated pathology in a mouse model of Huntington disease, Nat Med 10, 148-154.
211. Nandi, P. K., Bera, A., and Sizaret, P. Y. (2006) Osmolyte trimethylamine N - oxide converts recombinant alpha - helical prion protein to its soluble beta - structured form at high temperature, J Mol Biol 362, 810-820.
212. Hamada, D. and Dobson, C. M. (2002) A kinetic study of beta - lactoglobulin amyloid fibril formation promoted by urea, Protein Sci 11, 2417-2426.
213. Polano, M., Bek, A., Benetti, F., Lazzarino, M., and Legname, G. (2009) Structural insights into alternate aggregated prion protein forms, J Mol Biol 393, 1033-1042.
214. Vernaglia, B. A., Huang, J., and Clark, E. D. (2004) Guanidine hydrochloride can induce amyloid fibril formation from hen egg - white lysozyme, Biomacromolecules 5, 1362-1370.